Oct 2026· Clinical Cancer Research· pp. OF1-OF10· 0 citations
Medicine
TL;DR
Findings identify circulating ETP as a potential biomarker in ER+ metastatic breast cancer and support further investigation of its relationship with disease activity and the development of endotrophin-targeting agents.
Abstract
Purpose
Soluble factors emanating from fibroinflammatory processes are emerging as cancer biomarkers and therapeutic targets. Endotrophin (ETP), a collagen VI proteolytic fragment, is elevated in human breast cancer patients and drives tumor progression in rodent breast cancer models, an effect which neutralizing antibodies can abrogate. This implies that tracking or targeting elevated ETP levels could inform breast cancer therapeutic strategies. However, we lack precise knowledge about the impact of ETP in specific breast cancer subtypes and whether circulating levels provide predictive or prognostic information.
EXPERIMENTAL
Design
To address these gaps, we assessed circulating ETP levels among breast cancer patients (n=191 samples from 98 patients) undergoing various treatment modalities, as well as patients with ovarian neoplasia (n=29) and healthy controls (n=19).
Results
We observed higher circulating ETP levels in estrogen receptor-positive (ER+/HER2-) tumors compared with triple-negative breast cancer (TNBC) in both early-stage and metastatic settings (median [IQR]: 35.98 [25.31-55.05] vs. 19.67 [9.23-42.07] ng/mL, respectively). However, circulating ETP levels were associated with treatment response only in the metastatic setting. ETP was readily detected in tumor specimens (n=54) and adjacent benign sections (n=28) from various breast tumor types, suggesting that both autocrine and paracrine ETP production may be important drivers of tumor growth.
Conclusions
In summary, these findings identify circulating ETP as a potential biomarker in ER+ metastatic breast cancer and support further investigation of its relationship with disease activity and the development of endotrophin-targeting agents.
Cancer remains a critical global health concern due to late detection, drug resistance, and high mortality. Mesothelin (MSLN) is a glycoprotein highly expressed on the surface of various cancer cells, including those of ovarian, pancreatic, and gastric cancers. Thus, it could be a valuable target for both as a biomarke...
Manoj-Kumar Gupta, Ramakrishna Vadde, G. Nagaraju· MedComm· 0 citations
Introduction: Neutrophil extracellular traps (NETs) are web-like structures composed of decondensed chromatin and neutrophil granule proteins. Accumulating evidence suggests that NETs are involved in tumor progression, invasion, and metastasis in breast cancer. Therefore, investigating changes in NET formation during a...
A. Omar, N. Kabildina· Oncology, Nuclear Medicine a...· 0 citations
Breast cancer is one of the most common lethal malignancies in women. Identifying new molecular vulnerabilities to develop clinically actionable biomarkers and targeted treatments to improve patient outcomes is crucial in this disease. In recent years, neurofibromin (NF1), encoded by the neurofibromin 1 gene (NF1), who...
A. Parsyan· Critical reviews in oncology...· 0 citations
Breast cancer is the most common cancer in women and the second leading cause of cancer death in the United States. Breast cancer has multiple subtypes defined by the expression of the estrogen receptor (ESR1), progesterone receptor (PGR), and human epidermal growth factor receptor 2 (HER2). Among breast cancer subty...
Chung S. Lee, Huan Cao, Vannah Algador et al.· Cancer Epidemiology, Biomark...· 0 citations
BACKGROUND
Thyroid carcinoma (THCA) represents the most prevalent malignancy of the endocrine system. Although the majority of patients exhibit favorable clinical outcomes, a subset still faces significant clinical challenges, including distant metastasis, recurrence, and poor response to therapeutic interventions, all...
Liang Chen, Chao-Hon Fu, Yang Chen et al.· Advances in Clinical and Exp...· 0 citations
Background and Aims. Systemic hypercoagulability is a recognized hallmark of malignancy. Growing evidence suggests that markers of hemostatic activation may serve as surrogates for tumor aggressiveness and prognosis, other than thrombosis; however, a comprehensive characterization of this "hemostatic signature" within...
M. Marchetti· Bleeding Thrombosis and Vasc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.